Nurse Practitioner · Stanford, CA
NPI
1831569391
Since 2015
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
300 Pasteur Dr
Stanford, CA, 94305
Phone (650) 723-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$44K
491 services
Medicare patients, 2024
185
Average age 75
Drug cost, 2024
$18.5M
2,378 prescriptions
Company payments, 2025
$2,041
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Misty L Mahaffey was code 99215 (office e&m - established), 141 times for 53 patients. In total Misty L Mahaffey billed 491 services in 16 codes, and Medicare paid $44K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 141 | 53 | $143.05 | $20K |
| 99215 Office E&M - Established | Facility | 140 | 66 | $103.57 | $15K |
| 38222 Other Organ Systems | Facility | 63 | 62 | $55.37 | $3,489 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 36 | 16 | $22.69 | $817 |
| 99214 Office E&M - Established | Facility | 27 | 19 | $64.12 | $1,731 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 24 | 12 | $25.30 | $607 |
| 99212 Office E&M - Established | Facility | 12 | 12 | $24.69 | $296 |
By year: 2022 $15K for 251 services; 2023 $20K for 239 services; 2024 $44K for 491 services.
Medicare prescription drug claims, 2024
In 2024, the drug Misty L Mahaffey prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 174 prescriptions and refills. In total Misty L Mahaffey wrote 2,378 Medicare prescriptions that cost $18.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 174 | 174 | 31 | $2.9M |
| Acyclovir Generic | 163 | 349 | 60 | $3,069 |
| Hydroxyurea Generic | 149 | 358 | 57 | $3,928 |
| Eliquis Apixaban | 140 | 210 | 39 | $121K |
| Calquence Acalabrutinib Maleate | 139 | 146 | 18 | $2.1M |
| Brukinsa Zanubrutinib | 109 | 109 | 17 | $1.4M |
| Revlimid Lenalidomide | 109 | 109 | 28 | $1.9M |
| Pomalyst Pomalidomide | 87 | 87 | 22 | $1.8M |
| Venclexta Venetoclax | 80 | 80 | 17 | $741K |
| Imbruvica Ibrutinib | 67 | 71 | 12 | $1.1M |
| Lenalidomide Generic | 67 | 67 | 18 | $956K |
| Promacta Eltrombopag Olamine | 61 | 69 | Under 11 | $798K |
| Sprycel Dasatinib | 55 | 55 | Under 11 | $570K |
| Dexamethasone Generic | 52 | 71 | 21 | $928 |
| Imatinib Mesylate Generic | 40 | 45 | Under 11 | $44K |
Brand drugs: 1,325 claims; generic drugs: - claims; opioid claims: 54.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Misty L Mahaffey $2,041 ($2,041 in general payments such as food, travel and fees) from 17 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $381.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $381 |
| Janssen Biotech, Inc. JNJ | 6 | $306 |
| Syndax Pharmaceuticals, Inc. SNDX | 2 | $292 |
| Rigel Pharmaceuticals, Inc. RIGL | 6 | $256 |
| Daiichi Sankyo Inc. 4568.T | 8 | $216 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $155 |
| BeOne Medicines USA, Inc. ONC | 3 | $83.32 |
| Geron Corporation GERN | 1 | $66.12 |
| Abbvie Inc. ABBV | 2 | $54.19 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $48.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.